Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)
Regeneron Pharmaceuticals' (REGN) quarterly EBT Margin came in at 23.05% in Q1 2026, down 683.0% year-on-year from 3.95% in Q1 2025, and down 14.2% quarter-over-quarter from 26.87% in Q4 2025.
Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 23.05% for Q1 2026.
- On a quarterly basis, EBT Margin fell 683.0% year-over-year to 23.05% in Q1 2026; TTM through Mar 2026 was 34.56%, a 82.0% decrease from a year earlier, with the FY2025 full-year figure at 36.47%, up 281.0% from the prior year.
- EBT Margin fell to 23.05% in Q1 2026 per REGN's latest filing, from 26.87% in the prior quarter.
- Across five years, EBT Margin topped out at 2122.2% in Q1 2022 and bottomed at 22.28% in Q1 2024.
- The 5-year median for EBT Margin is 33.71% (2022), against an average of 233.03%.
- Across the five-year window, EBT Margin surged 207265 bps in 2022 and slumped 209507 bps in 2023, its largest moves.
- Year by year, EBT Margin stood at 1324.7% in 2022, then plunged by 97 bps to 33.42% in 2023, then dropped by 24 bps to 25.29% in 2024, then rose by 6 bps to 26.87% in 2025, then dropped by 14 bps to 23.05% in 2026.
- Per Business Quant, the three latest REGN EBT Margin figures stand at 23.05% (Q1 2026), 26.87% (Q4 2025), and 46.97% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 18.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.05% |
| Dec 31, 2025 | 26.87% |
| Sep 30, 2025 | 46.97% |
| Jun 30, 2025 | 41.32% |
| Mar 31, 2025 | 29.88% |
| Dec 31, 2024 | 25.29% |
| Sep 30, 2024 | 40.13% |
| Jun 30, 2024 | 45.90% |
| Mar 31, 2024 | 22.28% |
| Dec 31, 2023 | 33.42% |
| Sep 30, 2023 | 33.03% |
| Jun 30, 2023 | 34.29% |
| Mar 31, 2023 | 27.13% |
| Dec 31, 2022 | 1,324.70% |
| Sep 30, 2022 | 51.42% |
| Jun 30, 2022 | 33.71% |
| Mar 31, 2022 | 2,122.20% |
| Dec 31, 2021 | 50.56% |
| Sep 30, 2021 | 52.61% |
| Jun 30, 2021 | 73.03% |